Market Cap (In USD)
2295.00
Revenue (In USD)
-
Net Income (In USD)
-780.88 Thousand
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-4-0.0059
- PE
- -
- EPS
- -
- Beta Value
- 2.636
- ISIN
- US75915R1068
- CUSIP
- 75915R106
- CIK
- 1716324
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Robert J. Stubblefield CPA
- Employee Count
- -
- Website
- -
- Ipo Date
- 2019-05-29
- Details
- Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
More Stocks
-
PIQ
-
33637K
-
3593
-
BEEMBeam Global
BEEM
-
1566
-
ASSB
-
GPOXGPO Plus, Inc.
GPOX
-
7097